CCR6 and neoplasm: Indeed, under cisplatin treatment, there is a production of CCL20 and IL-1β by murine lung and breast cancer cells, which triggers the recruitment of the CCR6+ type 3 innate lymphoid cells (ILC3) at the tumor site.